View Item 

Show simple item record

Multicenter phase II study of brequinar sodium in patients with advanced lung cancer
dc.contributor.authorGyves, John W.en_US
dc.contributor.authorDallaire, Brianen_US
dc.contributor.authorSisk, Reginaen_US
dc.contributor.authorMorgan, Roberten_US
dc.contributor.authorMaroun, Jeanen_US
dc.contributor.authorRuckdeschel, Johnen_US
dc.contributor.authorNatale, Ronald B.en_US
dc.date.accessioned2006-09-11T18:23:14Z
dc.date.available2006-09-11T18:23:14Z
dc.date.issued1993-01en_US
dc.identifier.citationMaroun, Jean; Ruckdeschel, John; Natale, Ronald; Morgan, Robert; Dallaire, Brian; Sisk, Regina; Gyves, John; (1993). "Multicenter phase II study of brequinar sodium in patients with advanced lung cancer." Cancer Chemotherapy and Pharmacology 32(1): 64-66. <http://hdl.handle.net/2027.42/46927>en_US
dc.identifier.issn1432-0843en_US
dc.identifier.issn0344-5704en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/46927
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=8384937&dopt=citationen_US
dc.description.abstractA total of 53 patients with advanced lung cancer [non-small-cell (NSC), 21; small-cell (SC), 32] were treated with brequinar sodium. All of the NSC patients were chemotherapy-naive, but 31/32 (97%) SC patients had failed a multiagent chemotherapy program prior to study entry. Brequinar was given intravenously at a median weekly dose of 1200 mg/m 2 . The toxicity was moderate, with 19 patients (36%) experiencing grade 3 or 4 toxicity. Objective responses were observed in one NSC and two SC patients. We conclude that at this dose and on this schedule, brequinar does not have sufficient activity in patients with NSC or in patients with previously treated SC to warrant further evaluation. However, since responses were observed in previously treated SC lung-cancer patients, further evaluation in chemotherapy-naive patients may be warranted.en_US
dc.format.extent289506 bytes
dc.format.extent3115 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherSpringer-Verlagen_US
dc.subject.otherCancer Researchen_US
dc.subject.otherOncologyen_US
dc.subject.otherBiomedicineen_US
dc.subject.otherPharmacology/Toxicologyen_US
dc.titleMulticenter phase II study of brequinar sodium in patients with advanced lung canceren_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelRadiologyen_US
dc.subject.hlbsecondlevelChemistryen_US
dc.subject.hlbsecondlevelChemical Engineeringen_US
dc.subject.hlbsecondlevelBiological Chemistryen_US
dc.subject.hlbtoplevelEngineeringen_US
dc.subject.hlbtoplevelScienceen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumUniversity of Michigan, Ann Arbor, MI, USAen_US
dc.contributor.affiliationotherAlbany Medical Center, Albany, NY, USA; H. Lee Moffitt Cancer Center, Tampa, FLen_US
dc.contributor.affiliationotherOttawa Regional Cancer Center, Ottawa, Canadaen_US
dc.contributor.affiliationotherOncology, The DuPont Pharmaceutical Company, P. O. Box 80026, 19880-0026, Wilmington, DE, USAen_US
dc.contributor.affiliationotherCity of Hope National Medical Center, Duarte, CA, USAen_US
dc.contributor.affiliationotherOncology, The DuPont Pharmaceutical Company, P. O. Box 80026, 19880-0026, Wilmington, DE, USAen_US
dc.contributor.affiliationotherOncology, The DuPont Pharmaceutical Company, P. O. Box 80026, 19880-0026, Wilmington, DE, USAen_US
dc.contributor.affiliationumcampusAnn Arboren_US
dc.identifier.pmid8384937en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/46927/1/280_2004_Article_BF00685878.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1007/BF00685878en_US
dc.identifier.sourceCancer Chemotherapy and Pharmacologyen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
280_2004_Article_BF00685878.pdf
Size:
282.7KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.